Drug intelligence / Profile preview

INR-302

Development stage: Unknown
Lead developer: Imnewrun Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

INR-302 is an investigational monoclonal antibody developed by Imnewrun Biosciences. It functions as a programmed death-ligand 1 (PDL1) inhibitor and is being explored for the treatment of Alzheimer’s disease. The drug acts by targeting PDL1, a protein involved in immune checkpoint pathways that can modulate immune responses in the nervous system. As of the latest updates, its development status remains at the discovery stage with no clinical trial results reported[1][5].

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on INR-302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INR-302.

Explore the full profile